2-[(1H-benzimidazol-2-ylsulfinyl)methyl]benzenamine | 104340-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]benzenamine
• 英文别名: 2-<(1H-benzimidazol-2-ylsulfinyl)methyl>aniline；2-<(2-aminobenzyl)sulfinyl>-1H-benzimidazole；2-(2-aminobenzylsulfinyl)-benzimidazole；2-(2-aminobenzylsulfinyl)benzimidazole；2-[(1H-Benzimidazole-2-sulfinyl)methyl]aniline；2-(1H-benzimidazol-2-ylsulfinylmethyl)aniline
• CAS: 104340-34-3
• 化学式: C₁₄H₁₃N₃OS
• 分子量: 271.343
• InChiKey: INGIXPMMNAFVHF-UHFFFAOYSA-N

物化性质

• 熔点：
  164-165 °C
• 沸点：
  591.4±52.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  91
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(1H-benzimidazol-2-ylsulfinyl)methyl]benzenamine 在 盐酸 作用下， 以 水 为溶剂， 反应 3.0h， 以50.6%的产率得到1H-苯并咪唑-2-硫醇
  参考文献：
  名称：

  Amino acid amides of 2-[(2-aminobenzyl)sulfinyl]benzimidazole as acid-stable prodrugs of potential inhibitors of H+K+ ATPase

  摘要：

  A series of amino acid amides of 2-[(2-aminobenzyl)sulfinyl]benzimidazole were prepared and found to possess gastric antisecretory activity on oral administration. (Glycylaminobenzyl)sulfinyl compound 23a, stable in artificial gastric juice (pH 1.2), was given orally to dogs. It was absorbed efficiently and converted into aniline derivative 7a which showed a very high plasma concentration. Compound 23a was hydrolyzed by the action of aminopeptidase present in plasma or the brush border fraction of the small intestine to release the terminal glycine. omicron-Aniline derivatives showed good activity in in vitro H+/K+-ATPase inhibition as well as in the inhibition of histamine stimulated acid secretion in isolated bullfrog gastric mucosa. Although these omicron-aniline derivatives showed no or weak gastric antisecretory activity in rat by id administration, they were active when administered ip. Therefore, these amino acid amides were considered to be acid stable prodrugs of proton pump inhibiting omicron-aniline derivatives. The mechanism of H+/K+-ATPase inhibition of 7a was also examined.

  DOI：

  10.1016/0223-5234(91)90024-h
• 作为产物：
  描述：

  苄基[2-(羟基甲基)苯基]氨基甲酸酯 在 sodium hydroxide 、 氯化亚砜 、 氢溴酸 、 溶剂黄146 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 乙醇 、 氯仿 、 水 、 苯 为溶剂， 反应 6.5h， 生成 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]benzenamine
  参考文献：
  名称：

  Amino acid amides of 2-[(2-aminobenzyl)sulfinyl]benzimidazole as acid-stable prodrugs of potential inhibitors of H+K+ ATPase

  摘要：

  A series of amino acid amides of 2-[(2-aminobenzyl)sulfinyl]benzimidazole were prepared and found to possess gastric antisecretory activity on oral administration. (Glycylaminobenzyl)sulfinyl compound 23a, stable in artificial gastric juice (pH 1.2), was given orally to dogs. It was absorbed efficiently and converted into aniline derivative 7a which showed a very high plasma concentration. Compound 23a was hydrolyzed by the action of aminopeptidase present in plasma or the brush border fraction of the small intestine to release the terminal glycine. omicron-Aniline derivatives showed good activity in in vitro H+/K+-ATPase inhibition as well as in the inhibition of histamine stimulated acid secretion in isolated bullfrog gastric mucosa. Although these omicron-aniline derivatives showed no or weak gastric antisecretory activity in rat by id administration, they were active when administered ip. Therefore, these amino acid amides were considered to be acid stable prodrugs of proton pump inhibiting omicron-aniline derivatives. The mechanism of H+/K+-ATPase inhibition of 7a was also examined.

  DOI：

  10.1016/0223-5234(91)90024-h

文献信息

• Method of using (H.sup.+ /K.sup.+)ATPase inhibitors as antiviral agents
  申请人：G.D. Searle & Co.

  公开号：US05945425A1

  公开（公告）日：1999-08-31

  A class of compounds which are (H.sup.+ /K.sup.+)ATPase inhibitors can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula III: ##STR1## wherein D is N or CH; wherein R.sup.7 is one or more radicals selected from hydrido, alkoxy, amino, cyano, nitro, hydroxyl, alkyl, halo, haloalkyl, carboxyl, alkanoyl, nitro, amino, alkylamino, aminocarbonyl, aminosulfonyl, alkylaminocarbonyl, alkylcarbonylamino, alkoxycarbonyl, alkylaminosulfonyl, alkylsulfonylamino, alkylthio, alkylsulfinyl and alkylsulfonyl; wherein R.sup.8 is selected from hydrido, alkyl and cycloalkyl; wherein R.sup.9 is one or more radicals selected from hydrido, alkoxy, amino, alkyl, halo, cyano, nitro, hydroxyl, haloalkyl, nitro, carboxyl, alkanoyl, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, aminosulfonyl, alkylaminosulfonyl, alkylsulfonylamino, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; and wherein R.sup.10 and R.sup.11 are independently selected from hydrido, alkyl, aryl, alkylcarbonyl and arylcarbonyl wherein the aryl ring may be further substituted with one or more radicals selected from alkyl, halo, hydrazidylcarbonyl, aminocarbonyl and alkoxy; or wherein R.sup.10 and R.sup.11 together with the nitrogen atom form a heterocyclic ring.

  一类(H.sup.+ /K.sup.+)ATP酶抑制剂化合物可用于治疗病毒感染。特别感兴趣的化合物由Formula III定义：其中D为N或CH；其中R.sup.7为从氢化物、烷氧基、氨基、氰基、硝基、羟基、烷基、卤素、卤代烷基、羧基、烷酰基、硝基、氨基、烷基氨基、氨基甲酰基、氨基磺酰基、烷基氨基甲酰基、烷基羰基氨基、烷氧羰基、烷基氨基磺酰基、烷基磺酰胺基、烷硫基、烷砜基和烷磺酰中选择的一个或多个基团；其中R.sup.8选择自氢、烷基和环烷基；其中R.sup.9为从氢化物、烷氧基、氨基、烷基、卤素、氰基、硝基、羟基、卤代烷基、硝基、羧基、烷酰基、氨基、烷基氨基、二烷基氨基、氨基甲酰基、烷基氨基甲酰基、烷基羰基氨基、氨基磺酰基、烷基氨基磺酰基、烷基磺酰胺基、烷氧羰基、烷硫基、烷砜基和烷磺酰中选择的一个或多个基团；其中R.sup.10和R.sup.11分别选择自氢、烷基、芳基、烷基羰基和芳基羰基，其中芳环可能进一步取代一个或多个从烷基、卤素、肼基甲酰基、氨基甲酰基和烷氧基中选择的基团；或其中R.sup.10和R.sup.11与氮原子一起形成一个杂环环。
• [EN] METHOD OF USING (H/K) ATPase INHIBITORS AS ANTIVIRAL AGENTS<br/>[FR] PROCEDE D'UTILISATION D'INHIBITEURS DE (H/K)ATPASE COMME AGENTS ANTIVIRAUX
  申请人：G.D. SEARLE & CO.

  公开号：WO1995029897A1

  公开（公告）日：1995-11-09

  (EN) A class of compounds which are (H+/K+) ATPase inhibitors can be used for the treatment of viral infections. Compounds of particular interest are defined by formula (III), wherein D is N or CH; wherein R7 is one or more radicals selected from hydrido, alkoxy, amino, cyano, nitro, hydroxyl, alkyl, halo, haloalkyl, carboxyl, alkanoyl, nitro, amino, alkylamino, aminocarbonyl, aminosulfonyl, alkylaminocarbonyl, alkylcarbonylamino, alkoxycarbonyl, alkylaminosulfonyl, alkylsulfonylamino, alkylthio, alkylsulfinyl and alkylsulfonyl; wherein R8 is selected from hydrido, alkyl and cycloalkyl; wherein R9 is one or more radicals selected from hydrido, alkoxy, amino, alkyl, halo, cyano, nitro, hydroxyl, haloalkyl, nitro, carboxyl, alkanoyl, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, aminosulfonyl, alkylaminosulfonyl, alkylsulfonylamino, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; and wherein R10 and R11 are independently selected from hydrido, alkyl, aryl, alkylcarbonyl and arylcarbonyl wherein the aryl ring may be further substituted with one or more radicals selected from alkyl, halo, hydrazidylcarbonyl, aminocarbonyl and alkoxy; or wherein R10 and R11 together with the nitrogen atom form a heterocyclic ring; or a pharmaceutically acceptable salt thereof.(FR) Une classe de composés qui sont des inhibiteurs de (H+/K+)ATPase peut être utilisée pour le traitement d'infections virales. Les composés particuliers à examiner sont définis par la formule (III), dans laquelle D représente N ou CH; R7 représente un ou plusieurs radicaux choisis entre hydrido, alcoxy, amino, cyano, nitro, hydroxyle, alkyle, halo, haloalkyle, carboxyle, alcanoyle, nitro, amino, alkylamino, aminocarbonyle, aminosulfonyle, alkylaminocarbonyle, alkylcarbonylamino, alcoxycarbonyle, alkylaminosulfonyle, alkylsulfonylamino, alkylthio, alkylsulfinyle et alkylsulfonyle; R8 est choisi entre hydrido, alkyle et cycloalkyle; R9 représente un ou plusieurs radicaux choisis entre hydrido, alcoxy, amino, alkyle, halo, cyano, nitro, hydroxyle, haloalkyle, nitro, carboxyle, alcanoyle, amino, alkylamino, dialkylamino, aminocarbonyle, alkylaminocarbonyle, alkylcarbonylamino, aminosulfonyle, alkylaminosulfonyle, alkylsulfonylamino, alcoxycarbonyle, alkylthio, alkylsulfinyle, et alkylsulfonyle; et R10 et R11 sont indépendamment choisis entre hydrido, alkyle, aryle, alkylcarbonyle, et arylcarbonyle, le noyau aryle pouvant être en outre substitué par un ou plusieurs radicaux choisis entre alkyle, halo, hydrazidylcarbonyle, aminocarbonyle et alcoxy; ou R10 et R11 forment avec l'atome d'azote un noyau hétérocyclique; ou leur sel pharmaceutiquement acceptable.

  一类(H+/K+) ATPase抑制剂化合物可用于治疗病毒感染。特别感兴趣的化合物由公式(III)定义，其中D是N或CH；R7是一个或多个从氢基，烷氧基，氨基，氰基，硝基，羟基，烷基，卤基，卤基烷基，羧基，烷酰基，硝基，氨基，烷基氨基，氨基甲酰基，氨基磺酰基，烷基氨基甲酰基，烷基羰基氨基，烷氧羰基，烷基氨基磺酰基，烷基磺酰胺基，烷硫基，烷基亚磺酰基和烷基磺酰基中选择的基团；R8选择从氢基，烷基和环烷基中选择；R9是一个或多个从氢基，烷氧基，氨基，烷基，卤基，氰基，硝基，羟基，卤基烷基，硝基，羧基，烷酰基，氨基，烷基氨基，二烷基氨基，氨基甲酰基，烷基氨基甲酰基，烷氧羰基，烷基氨基磺酰基，烷基磺酰胺基，烷基亚磺酰基，烷氧羰基，烷硫基，烷基亚磺酰基和烷基磺酰基中选择的基团；R10和R11分别选择从氢基，烷基，芳基，烷基羰基和芳基羰基中选择，其中芳环可以进一步取代一个或多个从烷基，卤基，肼基羰基，氨基羰基和烷氧基中选择的基团；或者R10和R11与氮原子一起形成杂环环；或其药学上可接受的盐。
• Method of using (H+/K+) ATPase inhibitors as antiviral agents
  申请人：——

  公开号：US20010047038A1

  公开（公告）日：2001-11-29

  A class of compounds which are (H + /K + )ATPase inhibitors can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula III: 1 wherein D is N or CH; wherein R 7 is one or more radicals selected from hydrido, alkoxy, amino, cyano, nitro, hydroxyl, alkyl, halo, haloalkyl, carboxyl, alkanoyl, nitro, amino, alkylamino, amide, alkylamide, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; wherein R 9 is one or more radicals selected from hydrido, alkoxy, amino, alkyl, halo, cyano, nitro, hydroxyl, haloalkyl, carboxyl, alkanoyl, nitro, amine, alkylamine, dialkylamine, amide, alkylamide, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; and wherein R 10 and R 11 are independently selected from hydrido and alkyl; or a pharmaceutically acceptable salt thereof.

  一类(H+/K+)ATP酶抑制剂类化合物可用于治疗病毒感染。特别感兴趣的化合物由公式III:1定义，其中D为N或CH; R7为一个或多个基团，选自氢，烷氧基，氨基，氰基，硝基，羟基，烷基，卤素基，卤代烷基，羧基，烷酰基，硝基，氨基，烷基氨基，酰胺，烷基酰胺，烷氧羰基，烷基硫醇基，烷基亚砜基和烷基磺酰基; R9为一个或多个基团，选自氢，烷氧基，氨基，烷基，卤素基，氰基，硝基，羟基，卤代烷基，羧基，烷酰基，硝基，胺基，烷基胺基，二烷基胺基，酰胺，烷基酰胺，烷氧羰基，烷基硫醇基，烷基亚砜基和烷基磺酰基; R10和R11独立选择自氢和烷基; 或其药学上可接受的盐。
• Substituierte Toluidine, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Zubereitungen und ihre Verwendung als Magensäuresekretionshemmer
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0213474A2

  公开（公告）日：1987-03-11

  o-Toluidinderivate der Formel I worin A S, SO oder SO, bedeutet und R', R2, R3, R4, R5, R6, R7, R8, R13, R" und R15 für Wasserstoff und/oder definierte Substituenten stehen. Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Zubereitungen und deren Verwendung als Magensäuresekretionshemmer.

  式 I 的邻甲基苯胺衍生物 其中 A 是 S、SO 或 SO，R'、R2、R3、R4、R5、R6、R7、R8、R13、R "和 R15 是氢和/或定义的取代基。它们的制备工艺、含有它们的药物组合物以及它们作为胃酸分泌抑制剂的用途。
• Stabilized benzimidazole derivative and composition
  申请人：NIPPON CHEMIPHAR CO., LTD.

  公开号：EP0248634A2

  公开（公告）日：1987-12-09

  A stabilized physiologically active benzimidazole derivative having the formula (I): wherein R¹ is hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a fluoroalkyl group having 1 to 6 carbon atoms, a cycloalkyl group, phenyl group or an aralkyl group, R² is hydrogen atom or a lower alkyl group, or R¹ and R² together with the adjacent nitrogen atom form a ring, and each of R3a, R3b, R4a, R4b and R4c independ­ently is hydrogen atom, a halogen atom, a flouroalkyl group having 1 to 6 carbon atoms, a lower alkyl group, a lower alkoxy group, a lower alkoxycarbonyl group or an amino group. The stabilized benzimdazole derivative is in amorphous form or present in contact with a basic material.

  一种具有稳定生理活性的苯并咪唑衍生物，其式为(I)： 其中 R¹ 是氢原子、具有 1 至 8 个碳原子的烷基、具有 1 至 6 个碳原子的氟烷基、环烷基、苯基或芳烷基，R² 是氢原子或低级烷基，或 R¹ 和 R² 与相邻的氮原子一起形成一个环、R3a、R3b、R4a、R4b 和 R4c 各自独立地为氢原子、卤素原子、具有 1 至 6 个碳原子的氟烷基、低级烷基、低级烷氧基、低级烷氧羰基或氨基。稳定的苯并咪唑衍生物为无定形形式或与碱性物质接触存在。